Ginkgo Bioworks Reports Improved Q4 2024 Results

Ginkgo Bioworks Holdings, Inc. ( (DNA) ) has released its Q4 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors.

Ginkgo Bioworks Holdings, Inc. is a leading platform for cell programming and biosecurity, offering end-to-end services across various industries, including pharmaceuticals, agriculture, and specialty chemicals. The company is recognized for its innovative approach to solving biological challenges and its efforts in biosecurity infrastructure development.

In its latest earnings report, Ginkgo Bioworks announced a significant improvement in its financial performance for the fourth quarter of 2024, with total revenue reaching $44 million, marking a 26% increase from the previous year. The company also highlighted its successful restructuring efforts, which have led to improved cash flow and expanded cost savings targets.

Key financial metrics revealed a 29% growth in Cell Engineering revenue, driven by large biopharma customers, and a modest increase in Biosecurity revenue. Despite a net loss of $108 million for the quarter, this was a marked improvement from the $212 million loss in the same period last year. The company’s Adjusted EBITDA also showed progress, improving to a loss of $57 million from $101 million in the prior year.

Ginkgo Bioworks has made strategic advancements, including closing new deals in Cell Engineering and securing a significant contract for its Antibody Developability product. The company is also expanding its biosecurity efforts with a new contract from the European Health and Digital Executive Agency. Looking ahead, Ginkgo aims to achieve Adjusted EBITDA breakeven by the end of 2026, with a focus on cost-cutting and sustainable revenue generation.

As Ginkgo Bioworks moves into 2025, the company anticipates total revenue between $160 million and $180 million, with continued growth in its Cell Engineering and Biosecurity segments. The management remains committed to driving innovation and efficiency, positioning the company for a promising future in the synthetic biology landscape.